Anlotinib plus docetaxel in advanced NSCLC progressing on immunotherapy: A pooled analysis of two randomized trials
Wu, Lin, Fang, Yong, Pu, Xingxiang, Shou, Jiawei, Xiao, Zemin, Chen, Jun, Xiao, Maoliang, Guo, Qunyi, Ma, Zhongsha, Hong, Wei, Wang, Qianzhi, Wang, Yonghui, Li, Jia, Rao, Chuangzhou, Jie, Weng, Lu, Liqin
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
A multicenter, randomized, phase II trial of anlotinib plus docetaxel versus docetaxel in EGFR-negative NSCLC patients after progression on first-line platinum-base chemotherapy: ALTER-L018
Wu, Lin, Wu, Zhijun, Xiao, Zemin, Ma, Zhongsha, Weng, Jie, Chen, Yanhua, Cao, Yongqing, Cao, Peiguo, Xiao, Maoliang, Zhang, Hui, Duan, Huaxin, Wang, Qianzhi, Li, Jia, Xu, Yan, Pu, Xingxiang, Li, Kang
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018
Wu, Lin, Wu, Zhijun, Xiao, Zemin, Weng, Jie, Ma, Zhongsha, Chen, Yanhua, Xiao, Maoliang, Cao, Yongqing, Duan, Huaxin, Cao, Peiguo, Zhang, Hui, Wang, Qianzhi, Li, Jia, Xu, Yan, Pu, Xingxiang, Li, Kang
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
5-aza-2'-deoxycytidine suppresses the growth of human lung adenocarcinoma cells in nude mouse xenograft models and its effect on methylation status and expression of TFPI-2 gene
Liang, Jiangshui, Yin, Guilin, Dong, Yongqiang, Ma, Zhongsha, Xiao, Yuehua, Ji, Tao
Published in Zhōnghuá zhŏngliú zázhì (01.07.2015)
Get full text
Published in Zhōnghuá zhŏngliú zázhì (01.07.2015)
Journal Article